Nov 14, 2017 - Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Nov 07, 2017 - It was another lackluster quarter from the diabetes specialist.
Nov 06, 2017 - Earnings results largely guided stocks across Europe and China over last week.
Oct 30, 2017 - Not all diabetes stocks are created equally.
Oct 19, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
Oct 02, 2017 - Traders cheer after management provided investors with a series of positive updates.
Sep 06, 2017 - Last summer, the diabetes-focused pharmaceutical issued distressing guidance due to pricing pressure worries, but the forecast troubles failed to arrive.
Aug 22, 2017 - Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here's why they're worth putting on your radar.
Aug 14, 2017 - A solid-enough second quarter from the diabetes specialist boosts investors' confidence in a turnaround.
Aug 09, 2017 - Novo Nordisk A/S (NYSE:NVO) Q2 2017 Earnings Conference Call August 9, 2017 7:00 AM ET Executives Lars Fruergaard Jorgensen – President and Chief Executive Officer Mads Krogsgaard Thomsen – Executive